Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals

Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Nov. 9-21. Deal Watch is supported by deal intelligence from Strategic Transactions.

Bristol-Myers Squibb Co. is making a move into the fast-moving gut microbiome space in an immuno-oncology focused collaboration with...

More from Strategy

More from Business